4th Annual Pharmaceutical Strategic Pricing Conference

September 17-18, 2019 | Philadelphia, PA

Four Points by Sheraton City Center Hotel

Download AgendaRegister Now

DAY ONE | TUESDAY, SEPTEMBER 17

7:45 REGISTRATION & WELCOME COFFEE

8:30 CHAIRPERSON’S OPENING REMARKS

8:45 BENCHMARKING PREPAREDNESS FOR ABRUPT REGULATORY CHANGE
Mounting public pressure to slow the rate of rising drug costs is likely to change the way strategic pricing models are structured, as resulting regulations could restrict the tools and methods that are employed to determine a product’s price. Broad regulatory changes will introduce new challenges to the already intricate pricing process, requiring a skilled team of adaptable strategic pricing professionals. Following an overview of successful efforts to predict and implement sudden procedural change, participants will discuss internal preparation strategies and how to evolve alongside the regulated pricing processes.

Christopher Jackson, Partner, THE LAW OFFICE OF CHRISTOPHER S. JACKSON LLC

 

9:30 PANEL: MULTIPLE PERSPECTIVES ON MAINTAINING COMPLIANCE AND FLEXIBILITY ALONGSIDE REGULATORY UNCERTAINTIES
As pricing manufacturers adjusted negotiation practices to meet new guidance surrounding cooperation with PBMs, the decision to restrict certain rebates was pulled back, undermining the expectations of the industry as a whole. Uncertainty surrounding the viability of these proposals has introduced risk into established pricing structures and could alter the roles of companies involved in pricing negotiations. For further clarity on how partnering organizations have adjusted to this change, panelists from different positions throughout the pricing structure will discuss how internal operations have evolved to account for this regulatory ambiguity.

MODERATOR:
Thomas Barker, Partner, FOLEY HOAG

PANELISTS:
Amy Bricker, SVP, Supply Chain, EXPRESS SCRIPTS

Christopher Jackson, Partner, THE LAW OFFICE OF CHRISTOPHER S. JACKSON LLC

 

10:30 COFFEE AND NETWORKING BREAK

 

11:00 BOARDROOM: ESTIMATING IMPACT OF GENE THERAPY ON ESTABLISHED PRICING STRUCTURES
As an emerging technology with the potential to transform the health care industry, gene therapy is at the forefront of discussions surrounding the future of drug pricing. The expected high demand for this expensive, one-time curative treatment could significantly alter the way health care is valued, and professionals working in pricing negotiations require a tentative plan on how the new treatment’s cost should be approached. Following a brief overview on gene therapy and the questions it presents, a board-room style discussion will provide attendees with insight on how other manufacturers are preparing for the treatment’s introduction.

Aron Chuc, Senior Director of Pricing and Contracting, ALNYLAM PHARMACEUTICALS

 

11:45 LUNCHEON FOR ALL PARTICIPANTS

 

12:45 FIRESIDE CHAT: PERSPECTIVE ON REBATES IN MEDICARE PART D AND INTERNATIONAL PRICE INDEXING
The ability to predict economic conditions is an essential function of a strategic pricing professional’s role, but pending legislation and regulations could upend established pricing models and leave pricing experts with an ambiguous outlook on the future. Although the Department of Health & Human Services recently withdrew its proposed regulation effectively prohibiting rebates in Medicare Part D, the concept is still being considered by Congress in both Part D and the commercial insurance market. The potential for an international price indexing model also has the potential to change the established configuration of the pharmaceutical pricing process. Questions surrounding how both of the policies fit into the larger administration and Congressional efforts to enact drug pricing policies remain. An expert on these HHS proposals will join this session to provide an overview of the objectives behind this regulation and what it will mean for the future of pharmaceutical pricing in the United States.

  • Objectives behind the rebate regulation
  • Implications of adopting an IPI model
  • Explanation of implementation deadline

Thomas Barker, Partner, FOLEY HOAG

 

1:30 CASE STUDY: ICER’S OUTLOOK ON THE UPCOMING PUSH FOR VALUE-BASED PHARMACEUTICAL STRATEGIC PRICING
As advocacy for value-based pricing has increased in recent years, so too has ICER’s influence within governing bodies and the shaping of public opinion. The independent research organization’s involvement in regulatory developments has compelled pharmaceutical strategic pricing professionals to cooperate with and monitor its efforts closely in order to predict the evolving legal framework of pricing procedures. Following an in-depth look into the organization’s goals and point of view on key issues, delegates will have a chance to present questions to a representative familiar with ICER and gain a clearer view on what the institute has planned for the future.

Rena Conti, Associate Professor, BOSTON UNIVERSITY

 

2:15 COFFEE AND NETWORKING BREAK

 

2:45 PANEL: MANUFACTURER PERSPECTIVES ON THE IMPACT OF PRICING TRANSPARENCY EFFORTS
The heightening push for transparency in drug pricing has put manufacturers, payers and PBMs under the spotlight as regulators strategize how to put this public demand into law. While legislative efforts like the Flat Prices Act have compelled companies to be more open in pricing procedures, the fractured nature of the pricing environment has proved difficult for the public to feel fully informed and further legislation is expected. Representatives from PBMs, manufacturers and payers will converge to discuss expected changes in future pharmaceutical pricing and whether those outcomes will reflect a drug’s value.

  • Challenges of implementing transparent pricing
  • Projected outcomes of pricing transparency
  • Transparency’s link to value-based pricing

MODERATOR: Amy Peterpaul, HELSINN THERAPEUTICS

PANELISTS: John Alter, PFIZER

Brian Walls, PROGENICS PHARMACEUTICALS

Rich Sullo, FERRING PHARMACEUTICALS

 

3:45 STATE-LEVEL REGULATORY PUSH FOR TRANSPARENCY AND INDICATIONS OF FEDERAL CHANGE
While greater transparency is a specified goal of the federal government’s proposed regulatory efforts, state governments have led the charge in making pharmaceutical pricing processes more open and accountable. California’s SB-17 and other transparency-oriented bills are indicative of how lawmakers around the country are thinking about pharmaceutical pricing, as well as what steps manufacturers should take to prepare for forthcoming changes to pricing and contracting methods. Through an examination of the achievements and short-comings of these state-level changes, delegates will gain an informed perspective on the outcomes of specific legislative efforts and the likelihood of adoption at a federal level.

James Kim, Partner, MCDERMOTT WILL & EMORY

 

4:30 BENCHMARKING COMMUNICATION OF PRICING AND INTERNAL MARKETING COOPERATION
As rising out-of-pocket costs continue to escalate, public pressure on pharmaceutical manufacturers is at an all-time high. The complex and intertwined nature of the pricing process does not lend itself to transparency and has led to public insistence that lawmakers pass sweeping legislation that may not constructively address the issue. In order to combat this public interpretation, some pricing experts have begun working with internal marketing teams to communicate the pricing process and educate patients as to why prices do reflect value.

  • Overview of available communication tools
  • Collaboration with marketing teams
  • Methods of conveying pricing processes

Brian Walls, Executive Director, Pricing & Market Access
PROGENICS PHARMACEUTICALS

 

5:00 END OF DAY ONE CONFERENCE

Share This